<DOC>
	<DOCNO>NCT01751646</DOCNO>
	<brief_summary>This 48 week randomize double-blind , placebo-controlled prospective cohort study adolescent young adult HIV infection ATN currently treat cART include TDF one component regimen include least three Food Drug Administration ( FDA ) -approved ARVs least 180 day .</brief_summary>
	<brief_title>Vitamin D Absorption HIV Infected Young Adults Being Treated With Tenofovir Containing cART</brief_title>
	<detailed_description>This 48 week randomize double-blind , placebo-controlled prospective cohort study adolescent young adult HIV infection ATN currently treat cART include TDF one component regimen include least three Food Drug Administration ( FDA ) -approved ARVs least 180 day . Subjects must least one documented viral load 200 copies/mL collect follow initiation TDF contain cART great 90 day prior randomization ; viral load 200 copies/mL measure within 90 day prior randomization ; HIV viral load obtain screen 200 copies/mL . Treatment assignment balance subject sex birth , age ( &lt; 20 year vs. &gt; =20 year ) , race ( African American vs. ) . Enrolled subject randomize receive vitamin D3 50000 IU match placebo , give orally every four week DOT . In addition randomize study agent , subject receive MVI take orally daily . This `` standard '' MVI contain ingredient exceed 600 IU vitamin D3 200 mg Ca . DXA measurement whole-body BMC , BMD spine hip , perform baseline study week 24 48 . Blood urine sample assess Ca-PO4 axis , PTH-FGF23-vitamin D signaling , bone turnover , renal glomerular tubular function occur baseline study week 12 , 24 , 48 Blood sample measure Gluc homeostasis drawn baseline week 48 , run batch analysis . Safety , measure SCa SCr , monitor subject 's record review study site since lab generally measure part routine clinical care . The ATN109 study use SCa SCr value obtain within 10 week time visit begin baseline visit . If evaluation perform within prior 10 week draw time visit . Viral load CD4 cell count result record ATN109 study screening , baseline study week 12 , 24 , 48 , Post-Week 48 provided evaluation do within protocol specify timeframe . If evaluation perform within protocol specify timeframes drawn time visit .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>To consider eligible enrollment , individual must meet criterion list time randomization : NOTE : If DXA scan schedule prior randomization , , eligibility criterion must meet prior perform DXA scan . Age 16 year 0 day 24 year 364 day ; Behaviorally infect HIV ( e.g. , sexual contact , injection drug use ; infect perinatal transmission , blood transfusion , age young 9 year ) ; HIV1 infection document subject 's medical record least one follow criterion : reactive HIV screen test result antibody base FDAlicensed assay follow positive supplemental assay ( e.g. , HIV1 Western Blot , HIV1 Indirect Immunofluorescence , Antibody Differentiation Assay ( Multispot ) ) ; positive HIV1 DNA PCR assay ; plasma HIV1 quantitative RNA assay &gt; 1,000 copies/mL ; positive plasma HIV1 RNA qualitative assay Subjects must least one document HIV viral load 200 copies/mL collect follow initiation TDF contain cART great 90 day prior randomization ; HIV viral load 200 copies/mL measure within 90 day prior randomization ; HIV viral load obtain screen 200 copies/mL . Currently treat least 180 day time randomization TDF contain cART least 2 FDA approve ARVs ( NOTE : This may include TDFcontaining fixed drug combination medication ) ; Negative serum hepatitis B surface antigen ( HBsAg ) screen history within 4 week prior screen ( see section 7.1.3 ) ; Willingness ability remain cART regimen duration study participation ; Willingness ability participate study , follow study procedure duration study participation , provide write informed consent assent parental permission , applicable ; For female childbearing potential , agreement use minimum one proveneffective method birth control willingness postpone pregnancy duration study participation ( see section 5.3.2 permit hormonal contraceptive ) To consider eligible enrollment , individual must meet criterion list time randomization : NOTE : If DXA scan schedule prior randomization , eligibility criterion must meet prior perform DXA scan . Prior hypersensitivity vitamin D ; History sarcoidosis , arteriosclerosis , renal stone , glomerulonephritis , interstitial kidney disease , nephrotic syndrome , hypercalcemia , osteoporosis and/or bone disease , clinical diagnosis hypoparathyroidism hyperparathyroidism ; Lactation pregnancy currently within past 24 week ; Chemotherapy radiation therapy malignancy within past 12 month ; Known presence GI disease , opinion clinician , would interfere study agent administration absorption ( e.g . Crohn 's , Colitis ) ; For subject â‰¥ 18 year , confirm creatinine clearance &lt; 70 ml/min ( estimate GFR SCr use CG equation ) subject &lt; 18 year , confirm creatinine clearance &lt; 70ml/min/1.73m2 ( estimate GFR SCr use Schwartz formula ( see section 3.5 ) . ( Estimated GFR may calculate use formula program ATN website ; SCa &gt; Upper Limit Normal ( ULN ) local laboratory value ( see section 7.1.3 ) ; Active Grade 3 high clinical laboratory toxicity except ATV associate indirect hyperbilirubinemia ( see section 9.5.2.2 ) ; Weight &gt; 350 pound ( lb ) 159 kilogram ( kg ) ; Positive hepatitis C antibody history screening ( see section 7.1.3 ) ; Use medication specify section 5.3.1 , 5.3.3 5.4 . Females Only : Use certain hormonal contraceptive specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>